felin
viru
fiv
natur
infect
domest
cat
result
acquir
syndrom
resembl
human
viru
hiv
infect
human
worldwid
preval
fiv
infect
domest
cat
report
rang
henc
effect
fiv
vaccin
import
impact
veterinari
medicin
addit
use
small
anim
aid
model
human
sinc
discoveri
fiv
report
fiv
vaccin
research
pursu
molecular
convent
vaccin
approach
toward
develop
commerci
product
publish
fiv
vaccin
trial
result
present
compil
updat
veterinari
clinic
research
commun
immunolog
experiment
statu
vaccin
brief
report
includ
outcom
year
collabor
work
industri
academia
led
recent
usda
approv
anim
lentiviru
vaccin
dualsubtyp
fiv
vaccin
immunogen
experiment
prototyp
dualsubtyp
fiv
vaccin
current
approv
commerci
dualsubtyp
fiv
vaccin
felovax
fiv
discuss
potenti
crossreact
complic
commerci
fiv
diagnost
test
idexx
snap
combo
test
western
blot
assay
sera
previous
vaccin
cat
also
discuss
final
recommend
made
unbias
critic
test
new
fiv
vaccin
current
usda
approv
vaccin
futur
vaccin
develop
felin
viru
fiv
lentiviru
caus
chronic
progress
acquir
syndrom
domest
cat
resembl
human
viru
hiv
infect
human
pedersen
et
al
siebelink
et
al
fiv
report
worldwid
preval
rate
rang
ishida
et
al
yamamoto
et
al
similar
least
nine
subtyp
clade
clade
j
k
predomin
group
fiv
clade
clade
much
smaller
intraclad
heterogen
bachmann
et
al
inoshima
et
al
veterinari
immunolog
immunopatholog
yamaguchi
et
al
blackard
et
al
although
retrovirina
famili
oncoviru
felin
leukemia
viru
felv
fiv
close
resembl
hiv
morpholog
pathogenesi
genet
sequenc
bendinelli
et
al
yamamoto
result
increas
worldwid
preval
sever
diseas
develop
effect
vaccin
imper
veterinari
medicin
fauci
et
al
bendinelli
et
al
howev
effect
fiv
vaccin
develop
face
similar
challeng
obstacl
involv
broad
crosssubtyp
protect
individu
mutat
intersubtyp
recombin
effect
hiv
vaccin
develop
paper
review
clinic
diseas
manifest
produc
fiv
infect
similar
experienc
controversi
veterinari
vaccin
design
protect
bcell
tcell
multipl
approach
use
develop
effect
fiv
vaccin
process
involv
develop
usda
approv
commerci
dualsubtyp
fiv
vaccin
hallmark
infect
deplet
peripher
tcell
reduct
ratio
ackley
et
al
taniguchi
et
al
torten
et
al
hoffmannfez
et
al
decreas
tcell
count
infect
cat
report
natur
experiment
infect
ackley
et
al
hoffmannfez
et
al
howev
select
fiv
vaccin
strain
consist
produc
clinic
ill
character
recurr
high
fever
increas
incid
secondari
infect
leukopenia
loss
invers
callanan
et
al
diehl
et
al
even
loss
tcell
cytotox
tlymphocyt
ctl
activ
develop
earli
fiv
infect
persist
asymptomat
stage
similar
infect
song
et
al
antifiv
ctl
activ
gener
mediat
tcell
recogn
whole
viru
fiv
gag
env
protein
flynn
et
al
li
et
al
addit
tcell
fivinfect
cat
produc
solubl
suppressor
antivir
factor
resembl
antivir
factor
caf
produc
hivposit
individu
flynn
et
al
choi
et
al
infect
cat
possess
strong
thelper
activ
increas
gamma
interferon
product
earli
stage
fiv
infect
gradual
decreas
longterm
infect
torten
et
al
hoffmannfez
et
al
bendinelli
et
al
liang
et
al
tcell
dysfunct
respons
fivinfect
cat
close
mimic
hivposit
individu
rideout
et
al
gebhard
et
al
bcell
dysfunct
involv
suppress
primari
antibodi
respons
time
antigen
present
bcell
less
dramat
tcell
dysfunct
loss
invers
seem
primari
antibodi
respons
tdepend
antigen
taniguchi
et
al
torten
et
al
viru
neutral
vn
antibodi
fiv
develop
shortli
product
antifiv
ctl
provid
addit
immun
inoshima
et
al
nevertheless
fiv
infect
persist
infect
anim
steadili
destroy
immun
system
interestingli
elev
serum
igg
level
observ
infect
cat
indic
fivinduc
bcell
hyperact
similar
observ
hiv
hopper
et
al
ackley
et
al
highgrad
bcell
lymphoma
abnorm
site
also
report
cat
natur
experiment
fiv
infect
terri
et
al
callanan
et
al
thu
fivinduc
immunolog
diseas
paradox
sinc
hyperimmunoact
state
occur
shortli
concurr
sever
syndrom
infect
anim
present
immun
disord
close
resembl
present
human
aid
calabres
et
al
symptom
frequent
observ
clinic
case
fiv
infect
rel
mild
innocu
includ
gingiv
lymphadenopathi
margin
leukopenia
yamamoto
et
al
client
inform
seri
hartmann
long
asymptomat
phase
gener
persist
year
time
immun
system
becom
progress
damag
infect
anim
develop
persist
secondari
diseas
secondari
infect
frequent
becom
resist
antimicrobi
therapi
eventu
result
death
yamamoto
et
al
longterm
survivor
report
fivinfect
cat
similar
longterm
nonprogressor
report
hivposit
individu
bendinelli
et
al
hofmannlehmann
et
al
longterm
survivor
appear
make
sizabl
popul
natur
infect
pet
cat
surviv
mani
year
minim
clinic
diseas
contrast
higher
earlier
mortal
rate
report
infect
stray
cat
result
higher
exposur
secondari
infect
exacerb
fiv
diseas
yamamoto
et
al
similar
hiv
fiv
diseas
manifest
progress
viral
infect
promot
use
fiv
infect
cat
model
identifi
effect
hiv
vaccin
strategi
order
protect
household
indooroutdoor
pet
cat
popul
fiv
infect
control
increas
worldwid
preval
within
reservoir
stray
cat
popul
vaccin
develop
essenti
howev
vaccin
immun
depend
upon
healthi
immun
system
fiv
invad
destroy
monocytemacrophag
select
tcell
popul
within
immun
system
mutat
within
infect
host
cell
creat
divers
strain
vari
pathogen
characterist
addit
fiv
infect
bcell
english
et
al
consequ
vaccin
develop
becom
increasingli
achiev
give
rise
major
concern
regard
develop
safe
product
similar
question
aros
earlier
develop
commerci
veterinari
vaccin
felv
vaccin
leukocel
smithklin
beecham
anim
health
group
felin
infecti
periton
viru
fipv
vaccin
primucel
anim
health
marek
diseas
md
vaccin
chicken
experiment
simian
viru
siv
vaccin
like
fiv
felv
attack
destroy
band
tlymphocyt
monocyt
origin
releas
initi
vaccin
exhibit
margin
experiment
challeng
studi
recent
studi
newer
gener
vaccin
demonstr
improv
safeti
control
experiment
trial
legendr
et
al
hoover
et
al
spark
although
controversi
still
exist
experiment
trial
relat
natur
infect
norsworthi
spark
addit
felv
vaccin
associ
vaccineassoci
tumor
format
attribut
hyperprolif
state
caus
excess
immun
vaccin
formul
alum
hydroxid
base
adjuv
spark
hendrick
brook
adjuv
consid
probabl
caus
vaccineassoci
format
cat
hendrick
brook
moreov
new
survey
consist
cat
usa
canada
indic
incid
vaccineassoci
cat
lower
previous
report
cat
increas
gobar
kass
nevertheless
studi
need
resolv
issu
consequ
felv
vaccin
gener
recommend
cat
live
indoor
minim
risk
contract
diseas
maci
spark
felin
medicin
advisori
panel
similar
fiv
initi
target
cell
infect
corona
viru
fipv
initi
invad
monocyt
macrophag
produc
either
fatal
effus
wet
noneffus
dri
form
diseas
norsworthi
controversi
felin
vaccin
releas
primucel
consist
attenu
temperaturesensit
live
fipv
pathogen
free
spf
cat
administ
intranas
vaccin
exhibit
manufactur
studi
gerber
et
al
wherea
independ
experiment
studi
demonstr
vaccin
safeti
minim
fehr
et
al
scott
addit
studi
enhanc
fip
challeng
infect
observ
vaccin
anim
scott
et
al
mcardl
et
al
like
fiv
felv
md
viru
oncogen
herp
viru
serotyp
chicken
infect
tand
blymphocyt
produc
neuropathi
neoplasia
calnek
calnek
witter
venugop
viru
highli
cellassoci
produc
diseas
chicken
calnek
witter
contrari
popular
belief
vaccin
virus
infect
tand
blymphocyt
possibl
use
vaccin
antigen
inactiv
whole
viru
inactiv
infectedcel
vaccin
demonstr
experiment
clinic
trial
calnek
venugop
recent
md
vaccin
consist
either
live
attenu
serotyp
md
viru
nonpathogen
serotyp
avian
herp
virus
support
earlier
clinic
trial
result
calnek
consequ
md
vaccin
success
vaccin
effect
control
neoplast
diseas
man
anim
lend
strong
support
idea
vaccin
develop
possibl
virus
infect
arm
immun
system
tand
blymphocyt
venugop
overal
felv
fip
md
vaccin
demonstr
vaccin
virus
infect
destroy
immun
cell
develop
howev
exist
usda
approv
vaccin
virus
commerci
market
also
provid
optim
develop
effect
fiv
vaccin
promis
result
recent
siv
vaccin
studi
support
view
vaccin
aid
lentivirus
develop
johnston
flore
nabel
mooij
heeney
major
reduct
siv
diseas
viru
load
observ
vaccin
macaqu
use
either
vectorbas
vaccin
dna
vaccin
without
cytokin
adjuvant
viral
peptid
boost
johnston
flore
nabel
mooij
heeney
partial
protect
correl
strong
tcell
respons
johnston
flore
nabel
mooij
heeney
longterm
followup
anim
requir
determin
whether
control
viru
load
diseas
progress
maintain
without
addit
vaccin
although
steril
immun
observ
viru
virul
viral
challeng
dose
use
may
consider
higher
singl
natur
exposur
may
thu
repres
excel
vaccin
approach
candid
vaccin
protect
siv
infect
observ
attenu
delet
mutant
vaccin
daniel
et
al
desrosi
bolognesi
wyand
et
al
howev
approach
consid
impract
clinic
trial
human
result
preclin
studi
rais
three
import
point
vaccin
protect
diseas
easier
achiev
prevent
infect
ie
steril
immun
need
identifi
durat
partial
protect
need
test
vectorbas
dna
vaccin
approach
distinctli
heterolog
subtyp
clinic
isol
recent
fiv
vaccin
trial
result
present
summar
tabl
wherea
earlier
vaccin
trial
result
report
elsewher
elyar
et
al
brief
overview
tabl
suggest
major
success
achiev
experiment
fiv
vaccin
trial
made
inactiv
whole
viru
inactiv
infectedcel
convent
vaccin
sever
challeng
system
sever
challeng
system
includ
vivoderiv
inocula
heterolog
strain
clinic
isol
comparison
viral
peptid
vaccin
fare
poorli
tabl
studi
dna
vaccin
vector
vaccin
shown
promis
result
weaker
challeng
system
vaccin
prophylaxi
fiv
strain
use
vaccin
antigen
also
strain
sourc
challeng
inoculum
multipl
laboratori
demonstr
singlestrain
fiv
vaccin
protect
cat
homolog
strain
slightli
heterolog
differ
strain
fiv
challeng
subtyp
yamamoto
et
al
elyar
et
al
hosi
et
al
contrast
studi
show
enhanc
fiv
infect
even
homolog
challeng
hosi
et
al
elyar
et
al
karla
et
al
technic
differ
vaccin
inactiv
procedur
cell
type
use
grow
vaccin
viru
vaccin
schedul
adjuv
use
vaccin
dose
variabl
virul
fiv
strain
produc
result
vaccin
studi
hosi
et
al
one
studi
inactiv
whole
viru
vaccin
cat
exhibit
greater
protect
vitroderiv
homolog
challeng
fiv
pet
compar
virul
heterolog
fiv
challeng
fiv
fiv
hosi
et
al
nevertheless
even
virul
challeng
strain
reduct
viru
load
earli
invert
ratio
observ
whole
viru
vaccin
cat
compar
unvaccin
control
dnabas
vaccin
cat
howev
investig
report
partial
protect
homolog
challeng
fiv
dna
vaccin
fiv
strain
lockridg
et
al
inactiv
singlestrain
whole
viru
vaccin
protect
report
use
vivoderiv
inoculum
challeng
homolog
fiv
strain
commerci
fort
dodg
adjuv
cholera
toxin
ct
incomplet
freund
adjuv
ifa
oilwat
emuls
fiv
protein
coat
onto
biotinyl
homolog
rbc
homolrbc
b
fivpetaluma
pet
fivshizuoka
shi
fivglasgow
fivmilan
c
rectal
rect
intranas
intravagin
ivag
oral
po
rectal
immun
follow
either
ip
aeip
immun
sc
immun
follow
either
ivag
po
immun
aeivag
po
week
fivamsterdam
e
refer
ref
f
week
boost
given
mg
either
ifa
cholera
toxin
ifact
adjuv
use
sc
immun
follow
either
intravagin
scivag
oral
scpo
immun
g
four
control
immun
either
ifa
alon
ifa
ct
boost
week
combin
result
control
avail
h
four
protect
cat
studi
boost
vaccin
four
new
control
cat
immun
bsa
biotinyl
homolog
rbc
group
challeng
inoculum
dose
statist
differ
control
p
karla
et
al
target
lymph
node
tln
intranas
e
rectal
rect
contact
exposur
contact
expo
cat
infect
fiv
isol
isol
inform
avail
na
f
percent
protect
protect
enhanc
challeng
viru
load
observ
immun
group
g
refer
ref
h
immun
twice
either
alvacfiv
alvac
vector
pfu
follow
immun
icv
cell
three
protect
cat
boost
icv
challeng
second
time
distinctli
heterolog
fivbang
j
immun
either
pci
vector
pcinc
vector
day
follow
immun
recsu
day
aa
acid
peptid
second
conserv
region
fiv
surfac
env
multipl
antigen
peptid
region
map
surfac
env
palmitoyl
thioester
peptid
region
surfac
env
solubil
infect
crfk
cell
swfiv
recombin
vaccinia
viru
express
env
glycoprotein
cleavag
site
su
tm
protein
su
tm
fiv
gag
protein
deriv
sequenc
solubil
crfk
cell
protein
swcrfk
simian
viru
env
sivenv
phosphat
buffer
salin
pb
recombin
surfac
env
recsu
express
either
e
coli
baculoviru
express
system
cell
fiv
integras
gene
delet
din
provir
dna
fiv
revers
transcriptas
gene
delet
drt
provir
dna
control
consist
either
plasmid
pb
carrier
gold
particl
cultur
media
media
adjuv
adjuv
immun
none
plasmid
use
provir
dna
construct
minimalist
immunogen
gene
express
midg
vector
construct
fiv
env
gene
dna
coat
onto
gold
particl
bind
site
delet
infecti
molecular
clone
provir
dna
b
molecular
adjuvant
either
interleukin
dna
plu
dna
interferong
ifng
dna
vivoderiv
challeng
heterolog
fiv
strain
hesselink
et
al
matteucci
et
al
pu
et
al
singlestrain
vaccin
provid
adequ
protect
homolog
close
relat
strain
moder
greatli
heterolog
fiv
strain
elyar
et
al
hesselink
et
al
date
convent
inactiv
singlesubtyp
fiv
vaccin
molecularderiv
vaccin
plasmid
dna
recombin
vector
recombin
peptid
vaccin
untest
unsuccess
protect
cat
heterolog
subtyp
fiv
challeng
use
vivoderiv
inoculum
elyar
et
al
recent
studi
suggest
homolog
fiv
vaccin
protect
use
vitroderiv
inoculum
challeng
may
provid
protect
challeng
use
vivoderiv
inoculum
hesselink
et
al
matteucci
et
al
pu
et
al
vivoderiv
inoculum
consist
plasma
infectedcel
deriv
cat
infect
vivo
passag
laboratori
isol
contain
quasispeci
fiv
close
simul
natur
condit
studi
use
singlesubtyp
fiv
vaccin
consist
infectedcel
fiv
isol
spf
cat
protect
homolog
fiv
challeng
vivoderiv
inoculum
matteucci
et
al
place
freeroam
shelter
month
natur
fivinfect
cat
singlesubtyp
vaccin
protect
vaccin
group
cat
fiv
infect
rate
wherea
unvaccin
control
group
becam
infect
major
limit
inactiv
infectedcel
vaccin
short
durat
vaccin
immun
compar
inactiv
whole
viru
vaccin
matteucci
et
al
tellier
et
al
sinc
level
fiv
exposur
natur
transmiss
remain
unknown
evalu
use
contact
challeng
system
repres
ultim
test
commerci
fiv
vaccin
consequ
approach
singlestrain
fiv
vaccin
design
may
requir
develop
vaccin
provid
broad
spectrum
protect
common
fiv
subtyp
b
vivoderiv
inoculum
demonstr
synergist
protect
properti
multiserotyp
inactiv
whole
viru
md
vaccin
use
multiserotypemultisubtyp
vaccin
novel
idea
veterinari
medicin
venugop
multisubtyp
vaccin
approach
broaden
immun
protect
introduc
aid
vaccin
commun
use
fiv
vaccin
model
yamamoto
et
al
dualsubtyp
fiv
vaccin
consist
inactiv
subtyp
aand
subtyp
dinfectedcel
provid
protect
vitroderiv
homolog
strain
test
heterolog
strain
yamamoto
et
al
hohdatsu
et
al
improv
dualsubtyp
fiv
vaccin
consist
inactiv
whole
virus
subtyp
elicit
strong
antifiv
cellular
immun
broad
spectrum
vn
antibodi
activ
pu
et
al
addit
provid
broaden
protect
cat
homolog
heterolog
challeng
use
vivoderiv
inoculum
pu
et
al
howev
fiv
vaccin
yet
test
naturalexpos
fivinfect
anim
preced
use
whole
viru
vaccin
cat
establish
felv
vaccin
known
case
accident
infect
due
improp
inactiv
viru
report
felv
vaccin
improv
inactiv
method
vaccin
viru
better
adjuv
formul
inactiv
kill
vaccin
approach
continu
use
futur
veterinari
vaccin
develop
recent
veterinari
vaccin
develop
provid
protect
via
induct
antivir
humor
immun
vn
antibodi
vn
antibodi
approach
also
use
earli
hivsiv
vaccin
develop
howev
failur
experiment
demonstr
protect
use
surfac
envelopebas
vaccin
nonhuman
primat
lack
correl
vn
antibodi
product
protect
dampen
enthusiasm
toward
develop
vaccin
reli
mainli
antibodi
immun
johnston
flore
nabel
mooij
heeney
subsequ
aid
vaccin
commun
view
advoc
concept
vaccin
aid
virus
requir
strong
antivir
cellular
immun
confer
protect
johnston
flore
nabel
mooij
heeney
consequ
develop
vaccin
induc
cellular
immun
protect
recombin
vector
vaccin
dna
vaccin
becam
primari
focu
aid
vaccin
research
johnston
flore
nabel
schnell
mooij
heeney
dna
vaccin
primarili
elicit
cellular
immun
wherea
recombin
vector
vaccin
elicit
cellular
immun
addit
antibodi
aim
target
protein
johnston
flore
nabel
schnell
mooij
heeney
antibodi
level
depend
upon
physicochem
charact
express
level
nonvector
target
protein
reduct
viru
load
prevent
diseas
signssymptom
observ
anim
immun
dna
vaccin
although
complet
protect
achiev
either
hivor
sivinfect
nonhuman
primat
model
fivinfect
domest
cat
hosi
et
al
johnston
flore
nabel
mooij
heeney
sinc
singl
immun
correl
vaccin
protect
elud
aid
research
almost
two
decad
comprehens
primeboost
approach
incorpor
humor
cellular
immun
develop
aid
lentivirus
new
vaccin
approach
gener
involv
prime
dna
recombin
vector
vaccin
follow
viralvector
viral
subunit
protein
boost
induc
cellular
antibodi
immun
johnston
flore
nabel
schnell
mooij
heeney
current
aid
vaccin
research
suggest
thelper
tcell
ctl
activ
import
vaccin
immun
johnston
flore
nabel
mooij
heeney
ctl
strong
thelper
activ
fiv
observ
dna
recombin
vector
inactiv
whole
viru
vaccin
flynn
et
al
lockridg
et
al
pu
et
al
dunham
et
al
among
fiv
vaccin
design
vn
antibodi
induct
consist
cat
immun
convent
inactiv
viru
vaccin
follow
recombin
vector
vaccin
tellier
et
al
giannecchini
et
al
pu
et
al
although
inactiv
infectedcel
vaccin
may
induc
higher
vn
antibodi
level
compar
inactiv
whole
viru
vaccin
durat
protect
may
shorter
inactiv
infectedcel
vaccin
group
matteucci
et
al
unlik
human
aid
research
test
hiv
vaccin
antibodi
abil
neutral
laboratori
clinic
isol
fiv
vaccin
research
test
vaccin
antibodi
nonadapt
clinic
isol
matteucci
et
al
pu
et
al
fiv
laboratori
test
crossneutr
abil
sera
natur
experiment
infect
cat
clinic
laboratori
isol
inoshima
et
al
pu
et
al
laboratori
test
neutral
antibodi
nonadapt
clinic
isol
may
becom
valuabl
mechan
evalu
crossstrain
futur
commerci
fiv
vaccin
like
hiv
detect
titer
vn
antibodi
fiv
affect
type
indic
cell
lymphoid
cell
line
vs
nonlymphoid
crfk
cell
line
use
vn
assay
giannecchini
et
al
fiv
vn
assay
lymphoid
cell
line
report
produc
accur
titer
natur
infect
giannecchini
et
al
crossneutr
antibodi
analysi
clinic
isol
perform
sera
cat
immun
candid
fiv
vaccin
inactiv
dualsubtyp
viru
vaccin
inactiv
fiv
infectedcel
vaccin
matteucci
et
al
pu
et
al
candid
vaccin
reportedli
protect
cat
either
vivoderiv
heterolog
subtyp
fiv
strain
contact
challeng
natur
isol
matteucci
et
al
pu
et
al
howev
vn
antibodi
titer
analysi
conduct
homolog
fiv
viru
use
inactiv
fiv
infectedcel
vaccin
sera
giannecchini
et
al
studi
protect
correl
presenc
higher
vn
antibodi
titer
giannecchini
et
al
use
sera
inactiv
dualsubtyp
fiv
vaccin
cat
limit
number
homolog
heterolog
laboratori
isol
test
crossneutr
antibodi
pu
et
al
increas
type
level
vn
antibodi
heterolog
laboratori
isol
report
dualsubtyp
fiv
vaccin
compar
singlesubtyp
vaccin
support
current
concept
aid
lentivir
vaccin
protect
requir
arm
immun
pu
et
al
unlik
earlier
studi
commerci
felv
vaccin
newli
develop
fiv
vaccin
come
increas
scrutini
due
recent
advanc
human
nonhuman
primat
aid
research
includ
technic
improv
viru
detect
method
increas
understand
challeng
condit
upon
vaccin
hesselink
et
al
giannecchini
et
al
pu
et
al
demonstr
protect
homolog
heterolog
challeng
becom
standard
featur
aid
lentiviru
vaccin
develop
commerci
veterinari
use
usda
approv
veterinari
vaccin
depend
upon
demonstr
use
laboratori
grown
challeng
inoculum
hivsiv
studi
nonhuman
primat
vitro
studi
molecular
clone
laboratori
isol
accur
immunogen
virolog
activ
report
clinic
isol
dsouza
et
al
beaumont
et
al
furthermor
inactiv
whole
viru
siv
vaccin
studi
reveal
need
use
challeng
inoculum
grown
differ
cell
vaccin
viru
order
prevent
fals
protect
result
anticellular
activ
stott
consequ
recent
experiment
fiv
vaccin
studi
incorpor
four
approach
earli
passag
inoculum
grown
primari
peripher
blood
mononuclear
cell
pbmc
molecularli
clone
inoculum
vivoderiv
inoculum
contact
challeng
simul
natur
condit
yamamoto
et
al
matteucci
et
al
huisman
et
al
karla
et
al
matteucci
et
al
pu
et
al
four
approach
util
laboratori
grown
primari
pbmc
inoculum
proven
reproduc
inexpens
approach
high
titer
cellfre
inoculum
readili
produc
larg
quantiti
laboratori
grown
inoculum
allow
increas
titer
retent
longer
durat
time
cryopreserv
thu
screen
potenti
vaccin
conduct
afford
laboratori
grown
inoculum
follow
limit
test
vivoderiv
inoculum
contrast
laboratori
grown
inoculum
approach
vivoderiv
approach
produc
multipl
limit
inoculum
product
titer
retent
increas
cost
contact
challeng
studi
approach
produc
limit
feasibl
viru
transmiss
increas
cost
limit
vivoderiv
inoculum
includ
amount
inoculum
produc
limit
number
donor
anim
requir
obtain
plasma
cell
optim
virem
stage
high
titer
viru
consist
achiev
vivo
product
vivoderiv
inoculum
costli
technic
time
blood
collect
peak
viremia
biolog
effect
plasma
cellular
compon
inoculum
variabl
among
recipi
anim
limit
contact
transmiss
fiv
includ
potenti
prolong
exposur
period
possibl
year
seroconvers
natur
transmiss
dose
may
low
rapid
transmiss
fiv
rout
fiv
transmiss
may
limit
rate
fiv
transmiss
yamamoto
et
al
matteucci
et
al
anoth
approach
use
molecularli
clone
fiv
siv
shiv
siv
backbon
hiv
env
regulatori
gene
challeng
inocula
johnson
huisman
et
al
karla
et
al
girard
et
al
use
inocula
provid
valuabl
inform
virolog
pathogenesi
aid
lentivirus
zou
et
al
lockridg
et
al
howev
controversi
arisen
use
inocula
vaccin
challeng
recent
highlight
experiment
vaccin
trial
use
shiv
challeng
nicodemu
et
al
garrett
underli
concern
clone
challeng
inocula
mimic
natur
transmiss
thu
protect
may
potenti
easier
achiev
primari
isol
wild
type
inocula
consist
quasispeci
although
use
pathogen
clone
viru
provid
rapid
readout
vaccinemedi
protect
clinic
diseas
addit
concern
pathogen
clone
recapitul
prolong
cours
hiv
infect
human
nicodemu
et
al
garrett
mani
vaccin
design
provid
steril
immun
follow
administr
howev
absenc
steril
immun
recent
aid
vaccin
studi
advoc
vaccin
base
prevent
diseas
manifest
johnston
flore
nabel
mooij
heeney
use
highdos
challeng
virul
strain
major
reduct
viru
load
loss
observ
diseaseprotect
vaccin
anim
compar
unvaccin
anim
johnston
flore
nabel
dunham
et
al
mooij
heeney
durat
reduc
viral
load
still
unknown
johnston
flore
mooij
heeney
highdos
vivo
inoculum
andor
earli
passag
select
fiv
strain
consist
caus
clinic
ill
addit
loss
invers
callanan
et
al
diehl
et
al
use
highdos
challeng
highli
virul
challeng
strain
may
requir
standard
judg
vaccin
sinc
vaccin
may
abl
provid
complet
protect
rigor
challeng
vaccin
evalu
base
effect
viru
load
count
ratio
fiv
antibodi
titer
activ
infect
controversi
current
exist
frequenc
vertic
transmiss
experiment
condit
transmiss
domest
cat
natur
serosurvey
young
kitten
suggest
vertic
transmiss
fiv
uncommon
yamamoto
et
al
lawler
evan
direct
exposur
fivposit
saliva
blood
via
bite
wound
consid
major
mode
natur
transmiss
transmiss
mode
includ
exposur
contamin
saliva
blood
groom
share
commun
food
lawler
evan
observ
support
experiment
studi
use
oral
inocul
fivinfect
blood
elyar
et
al
obert
hoover
burkhard
et
al
oral
inocul
dose
need
infect
much
higher
compar
dose
requir
parenter
intraven
intraperiton
inocul
elyar
et
al
obert
hoover
burkhard
et
al
intraven
iv
inocul
requir
smallest
inoculum
dose
elyar
et
al
hartmann
et
al
thu
natur
fiv
transmiss
limit
dose
present
saliva
peripher
blood
combin
rout
exposur
seen
experiment
contact
studi
salivari
fiv
level
may
low
rapid
transmiss
fiv
blood
level
may
higher
fiv
saliva
level
exposur
blood
limit
presenc
open
lesion
appropri
aggress
behavior
expos
intact
spf
male
cat
natur
infect
cat
oral
lesion
natur
infect
intact
male
cat
may
increas
rate
transmiss
howev
contact
exposur
studi
intact
male
cat
may
rais
ethic
issu
nevertheless
epidemiolog
survey
fivposit
cat
suggest
fiv
infect
occur
frequent
male
cat
ratio
compar
femal
cat
stray
cat
compar
household
cat
support
current
view
male
cat
aggress
behavior
predispos
factor
infect
contact
studi
essenti
determin
valu
fiv
vaccin
protect
cat
natur
transmiss
compar
felin
virus
felv
fip
felin
herp
viru
contact
transmiss
fiv
requir
longterm
exposur
month
year
natur
infect
cat
accord
contact
studi
epidemiolog
survey
diseas
manifest
common
earli
phase
natur
infect
support
view
natur
transmiss
occur
low
dose
hartmann
matteucci
et
al
addit
prerequisit
prolong
exposur
period
question
also
aris
concern
dose
requir
natur
transmiss
remain
elus
virul
natur
occur
popul
mainten
high
viru
load
differ
fiv
strain
oppos
laboratori
strain
consequ
moder
approach
use
appropri
fiv
isol
dose
produc
decreas
week
postinocul
without
invers
may
necessari
realist
approxim
natur
transmiss
initi
screen
individu
cat
infect
although
contact
challeng
studi
natur
transmiss
may
feasibl
commerci
vaccin
valid
due
prolong
exposur
period
obstacl
preclud
research
test
commerci
vaccin
contact
challeng
sinc
contact
challeng
system
close
mimic
natur
condit
reproduc
independ
studi
becom
increasingli
import
futur
improv
qualiti
new
commerci
vaccin
establish
vaccin
unlik
standard
felv
diagnost
detect
viral
antigen
blood
tear
current
fiv
diagnost
reli
detect
fivantibodi
peripher
blood
felin
medicin
advisori
panel
hartmann
et
al
fiv
infect
releas
level
viru
circul
convent
enzym
immunoassay
eia
detect
viral
antigen
consist
sensit
pcrbase
assay
use
detect
fiv
infect
experiment
infect
cat
vahlenkamp
et
al
klein
et
al
klein
et
al
pedersen
et
al
sensit
assay
compar
fiv
antibodybas
commerci
assay
prior
use
due
expens
sensit
assay
compar
convent
assay
recent
approv
pcrbase
assay
diagnost
set
preced
use
assay
system
addit
test
antibodybas
assay
eia
assay
western
blot
analysi
current
use
bootman
kitchin
impact
current
antibodybas
fiv
diagnost
vari
accord
type
fiv
vaccin
releas
commerci
use
convent
inactiv
fiv
vaccin
releas
year
major
current
fiv
diagnost
includ
western
blot
analysi
fig
vaccin
depend
antigen
level
commerci
vaccin
induc
broad
spectrum
antibodi
product
differ
fiv
protein
longlast
titer
howev
appropri
inactiv
vaccin
result
viral
antigen
genom
product
pcrbase
assay
convent
eia
assay
contrast
live
attenu
vaccin
caus
current
commerci
fiv
diagnost
also
potenti
may
aris
futur
viral
pcror
proteinbas
diagnost
depend
upon
level
attenu
sinc
current
approach
test
attentu
fiv
vaccin
base
viral
regulatori
gene
delet
mutant
attentu
viru
contain
gene
viral
structur
protein
detect
current
fiv
diagnost
improperli
attenu
vaccin
use
immunocomprom
host
vaccin
viru
may
escap
host
comprom
immun
system
produc
vaccin
viru
circul
interfer
current
well
futur
diagnost
veterinari
viru
vaccin
either
convent
inactiv
whole
viru
live
attenu
viru
vaccin
usda
last
year
live
recombin
vector
vaccin
introduc
veterinari
market
yamanouchi
et
al
usda
van
kampen
notabl
widespread
veterinari
vector
vaccin
rabi
vaccin
vector
vaccinia
fowlpox
canarypox
virus
virul
unnatur
host
recombin
vector
vaccin
incorpor
gene
sequenc
target
viral
protein
vector
genom
region
interfer
target
gene
express
schnell
incorpor
gene
must
includ
gene
protect
fivepitop
must
express
level
vaccin
host
mount
immun
respons
predomin
ctl
vn
antibodi
epitop
resid
fiv
gag
protein
envelop
glycoprotein
respect
lombardi
et
al
egberink
et
al
flynn
et
al
viral
protein
also
make
structur
protein
contain
major
epitop
immunodiagnost
although
vector
vaccin
gener
known
abil
gener
cellular
immun
compar
humor
immun
antibodi
target
viru
produc
use
vaccin
system
thu
current
fiv
diagnost
test
must
made
detect
fiv
antibodi
viral
protein
activ
infect
instead
fivantibodi
present
target
gene
product
express
vaccin
vector
contrast
recombin
vector
vaccin
minim
viral
pcrand
proteinbas
diagnost
vector
viru
use
preferenti
infect
describ
nonleukocyt
avian
pox
virus
target
protein
releas
circul
sinc
discoveri
fiv
goal
fiv
vaccin
studi
identifi
effect
vaccin
design
may
serv
model
effect
hiv
vaccin
design
human
develop
effect
fiv
vaccin
pet
cat
recent
unit
state
depart
agricultur
approv
usda
fort
dodg
anim
health
felovax
fiv
dualsubtyp
fiv
vaccin
led
commerci
releas
vaccin
fort
dodg
anim
health
fdah
fort
dodg
ia
juli
without
addit
boost
protect
rate
dualsubtyp
fiv
vaccin
year
fig
fiv
immunoblot
commerci
fiv
test
result
cat
immun
dualsubtyp
fiv
vaccin
experiment
infect
fiv
pet
cid
sera
test
fiv
antibodi
cat
two
experiment
immun
two
differ
sourc
dualsubtyp
fiv
vaccin
immunoblotsnap
combo
lane
b
c
experiment
infect
fiv
immunoblotsnap
combo
lane
e
f
sera
test
presenc
fiv
antibodi
use
immunoblot
analysi
commerci
idexx
snap
tm
combo
felv
fiv
test
kit
immunoblot
analysi
perform
serum
dilut
use
publish
method
pu
et
al
snap
test
perform
recommend
idexx
laboratori
inc
dualsubtyp
fiv
vaccin
produc
fort
dodg
anim
health
commerci
compani
usda
approv
product
lane
b
produc
laboratori
lane
c
shown
comparison
immunogen
dualsubtyp
fiv
vaccin
previous
report
pu
et
al
snap
test
immunoblot
result
demonstr
vaccin
cat
develop
antibodi
reactiv
current
fiv
diagnost
vaccin
induc
antibodi
full
spectrum
fiv
antigen
includ
antibodi
envelop
interestingli
cat
immun
usda
approv
dualsubtyp
fiv
vaccin
consist
longlast
antibodi
envelop
compar
cat
immun
experiment
dualsubtyp
fiv
vaccin
cat
vs
cat
posit
year
postvaccin
cat
intramuscular
heterolog
fiv
challeng
fort
dodg
anim
health
challeng
inoculum
result
infect
rate
cat
unvaccin
control
cat
second
trial
use
slightli
vaccin
immun
schedul
ie
instead
week
old
kitten
protect
rate
vaccin
kitten
rose
cat
heterolog
challeng
compar
infect
rate
cat
unvaccin
control
cat
year
fort
dodg
anim
health
although
vaccin
appear
provid
immun
least
year
contact
exposur
trial
simul
natur
transmiss
need
compliment
parenter
challeng
inocul
perform
fdah
consequ
felv
vaccineassoci
releas
commerci
veterinari
fiv
vaccin
rais
similar
concern
polici
adopt
veterinari
practition
felv
vaccin
administr
probabl
appli
fiv
vaccin
administr
impact
current
fiv
diagnost
test
import
issu
requir
care
monitor
practition
fiv
diagnost
requir
molecular
technolog
develop
advanc
assay
increas
sensit
must
keep
abreast
develop
releas
new
commerci
fiv
vaccin
equal
import
develop
commerci
produc
reliabl
safe
vaccin
veterinari
commun
fiv
research
must
continu
educ
aid
commun
promot
valu
fiv
vaccin
model
hiv
vaccin
develop
